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Optimisation and feature selection of poly-beta-
amino-ester as a drug delivery system for
cartilage†
Stefano Perni and Polina Prokopovich *
Drug localisation is still one of the main challenges in treating pathologies affecting cartilage; poly-beta-
amino-esters (PBAEs) drug conjugates are a possible solution; however, their efficacy highly depends on
the polymer structure hence the full potential of this delivery system is still unknown. For the purpose of
optimising the delivery system design, a large library of PBAEs was synthesised and dexamethasone
(DEX) uptake in cartilage was determined. All three components of PBAE (amine, acrylate and end-
capping) impacted the outcome. The most effective PBAE identified enhanced DEX uptake by 8 folds
compared to an equivalent dose of the commercial formulation and also prevented, through delivery of
DEX, the cartilage degradation caused by IL-1a (interleukine1a). A chemometrics based predictive model
was constructed and PBAEs properties most affecting the performance of the drug delivery systems
were identified. This model will allow further computer based PBAEs optimisation and fast track the
bench to market process for this delivery system.
1 Introduction
Cartilage is the connective tissue that constitutes the load-
bearing surfaces of synovial joints; it has no blood vessels
supply and mainly consists of extracellular matrix and chondro-
cytes. Cartilage main function is to allow low friction in synovial
joints and facilitates pain-free movements. The structure of the
extracellular matrix (ECM) of cartilage is characterised by the
presence of glycosaminoglycans (GAGs),1 these are polymers made
of amino sugars and uronic sugars or galactose. GAGs are highly
negatively charged allowing cartilage to perform the required
functions such as shock absorbance2,3 and exhibiting low contact
friction.4
Osteoarthritis (OA) is a common disease affecting cartilage
and consists of the thinning or loss of tissue resulting in bone
against bone articulation. The consequences of OA are pain,
swelling and difficulties in joint movement; thus, despite not
been life threatening, OA can have severe consequence on quality
of life and high societal costs caused by the loss of productivity of
affected patients or carers.5,6 Furthermore, because body mass
index (BMI) and age are well known risk factors for OA,7–9 the
prevalence of OA is expected to rise in the future in light of the
ageing population and increasing obesity. Currently, there are no
disease-modifying treatments for OA and only therapies capable
of providing short-term relief of pain and inflammation are
available, for example intra-articular steroidal injections to
reduce swelling and analgesic.10 These clinically available therapies
can only treat OA symptoms but are not curative. Another obstacle
to the effective management of OA is the difficulty in delivering any
agent in cartilage because of their lack of blood vessels and
composition. ECM of cartilage prevents drugs molecules present
in the intra-articular space from penetrating the tissue, hence drug
uptake is low and the majority of the active molecule diffuses
throughout the body.11–13 This problem is aggravated further by
the fact that many of drugs used to treat arthritis have serious side
effects, i.e. dexamethasone (DEX) has been linked to bone loss,
muscle weakness and atrophy, suppression of the adrenal gland,
increased risk of infection, peptic ulcer disease and growth
retardation.14 The development of a delivery system capable of
increasing the partitioning of drugs between cartilage tissue and
external fluid would enable the effective delivery of molecules
with potential effect on the metabolism of chondrocytes. Drug
localisation would also result in a reduced amount of drug
dispersed, and consequently, a lower incidence of side effects
and treatment costs.15
Poly-beta-amino-esters (PBAEs) are a class of polymers obtained
from the co-polymerisation of di-acrylates and amines.16 These
molecules can be further end-capped and possess positive charges
as well as being soluble in aqueous solutions.17 They have been the
subject of numerous studies employing them as DNA delivery
systems.18,19 The biocompatibility and dissolvability of PBAEs are
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the main benefits of these electrolytes compared to other available
poly-cations such as: poly-L-lysine and polyethyleneimine (PEI).20,21
Furthermore, depending on the amine and acrylate building
blocks, they are also inexpensive. A prodrug made covalently
binding dexamethasone, a clinically used steroid employed in
OA management, to poly-beta amino esters (PBAE–DEX) has
been shown to enhance the cartilage uptake of the drug.22 This
technology employs the electrostatic interaction between the
positively charged PBAEs and the negative constituents of cartilage
(GAGs) to increase the partitioning of the drug between the
synovial fluid and the cartilage tissue (Fig. 1). Moreover, DEX
elution from cartilage has been found to be slower when PBAE
prodrugs are employed and no cytotoxicity was detected towards
chondrocytes.22 Additionally, despite the mechanism of action
relying on the presence of the negatively charged GAGs, PBAE–
DEX still provided an effective drug delivery system in GAG-
depleted samples (mimicking osteoarthritis).22
Because of the urgent need for an effective drug delivery
system for cartilage, other systems have also been developed.
They are generally based similar working principles as PBAEs, for
example avidin,11,23–25 cationic peptide carriers26 and polyamido-
amine dendrimers.27 Cartilage localisation of DEX through PBAEs
or avidin was achieved through conjugation of the drug molecule
to the carrier polymer with a hydrolysable bond allowing the
release of the cargo from the delivery system once driven inside
the cartilage tissue. The relative low cost and ease of production
are advantageous characteristics of PBAEs over other approaches.
Furthermore, the cartilage targeting efficacy of only a few PBAEs
have been tested so far; however, the properties of PBAEs depend
on the three main constituents on the polymer chain, nominally
the acrylate, the amine and the end-capping agents. Therefore, we
hypothesised that the efficacy of PBAEs as drug delivery for
cartilage would also depend on all three building blocks and
that an optimal PBAE could be identified through combinatorial
chemistry. This would allow both the maximisation of the
opportunities provided by PBAEs and a fairer comparison with
other cartilage targeting technologies. With this in mind, the
primary objective of this study was the synthesis of a library of
PBAE–DEX conjugates and their ex vivo testing to optimise the
PBAE structure. The secondary objective was to assess the ability
of the promising PBAE identified to inhibit/reduce cartilage
ECM proteolysis induced by IL-1a, a pro-inflammatory cytokines
found in high concentrations in synovial fluids after a traumatic
joint injury28,29 often a leading cause of acute OA. Moreover, a
predictive model of PBAEs efficacy as drug delivery system for
cartilage based on the polymer chemical-physical characteristics
was developed through chemometrics. This model was employed
for the identification of PBAEs properties pivoting efficacy (feature
selection) and will enable further computational drug discovery
and optimal design of this delivery system reducing the time-
consuming and costly real-life screening of polymers.
2 Experimental
2.1 Chemicals
All amine, acrylate and end-capping compounds for the synthesis
of PBAE, succinic anhydride, 4-dimethylamino-pyridine, N,N0-di-
cyclohexylcarbodiimide and N-hydroxysulfosuccinimide, DMSO-d6,
fluorescein diacetate, propidium iodide, sodium acetate, Na2HPO4
and NaH2PO4 employed were purchased by Sigma, UK. Solvents for
the polymer synthesis, conjugation and HPLC mobile phase
(dichloro-methane, diethyl-ether and N,N-dimethyl-formamide,
acetonitrile, glacial acetic acid) were purchased by Fisher, UK.
All chemicals were used as received and stored as recom-
mended by the manufacturer.
2.2 Polymer synthesis
Acrylate-terminated poly(b-amino ester)s were synthesized by
mixing diacrylate and amine monomers in a 1.1 : 1 ratio. In a
typical synthesis, 3.70 mmol of acrylate were mixed with
3.36 mmol of amine in 5 mL of dichloro-methane (DCM). The
polymerization was then performed under stirring at 50 1C for
48 hours. PBAEs were precipitated pouring the reaction mixture
in about 50 mL of diethyl-ether and the solvent removed under
vacuum.22 The end-capping reaction was performed mixing the
acrylate-terminated PBAEs with excess of end-capping agent.22
The PBAE structure will be denoted throughout the text
using a letter referring to the diacrylate and a number (Fig. 2)
referring to the amine; for example A5 is the PBAE obtained from
1,4-butanediol diacrylate and 3-(dimethylamino)propylamine. This
will be followed by e1 for PBAE end-capped with ethylene-diamine
and e2 for PBAE end-capped with diethylene-triamine.
2.3 Dexamethasone succinylation
200 mg of dexamethasone (DEX) was succinylated (DEX-succ)
with succinic anhydride (200 mg) in the presence of 10 mg of
4-dimethylamino-pyridine (DMAP) in 50 mL of N,N-dimethyl-
formamide (DMF). The reaction was performed under nitrogen
for 24 h at room temperature with mixing and the solvent was
removed under vacuum (in a rotary evaporator).22
2.4 Conjugation of DEX to PBAEs
DEX-succ (8 mg) was conjugated to amine end-capped PBAE
(80 mg) with N,N0-dicyclohexylcarbodiimide (DCC) (8 mg) and
Fig. 1 Conceptual representation of drug delivery system working principles.
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N-hydroxysulfosuccinimide (NHS) (8 mg) in DCM (25 mL).
Conjugates PBAEs-drug were precipitated in diethyl-ether (250 mL)
and the solvent removed under vacuum.22
2.5 PBAE characterization
The hydrodynamic size (Dynamic Light Scattering (DLS)) and
zeta potential of un-capped (acrylated terminated) PBAEs dissolved
in 100 mM phosphate buffer (pH = 6.0) at about 20 mg mL1
were measured using a Malvern Zetasizer Nano ZS (Malvern
Instruments, Malvern, UK); zeta potentials were calculated
using the Smoluchowsky model.
Molecular weight of each PBAE in the library was determined
by gel permeation chromatography (GPC) using a Shimadzu-LC-
20Ai system equipped with a SuperdexTM 75 10/300 GL column;
the mobile phase was 100% sodium acetate buffer pH = 5 eluted at
1 mL min1. Number-averaged (Mn) and weight-averaged molecu-
lar weight (Mw) were calculated using PEG standards. Because the
molar masses were measured by GPC, they are not the real values
but only apparent values due to the use of PEG standards and due
to possible different hydrodynamic volumes of PEG standards and
poly(beta-amino esters) of identical molar mass.
1H-NMR spectroscopy was performed (Bruker BioSpin
GmbH) to identify the structures and estimate drug load of the
conjugated PBAE–DEX. Samples were prepared at 10–12 mg mL
in DMSO-d6.
2.6 Cartilage samples
Articular cartilage explants were surgically removed under sterile
conditions from metacarpo-phalangeal joints of bovine steers
immature (7 day-old) feet obtained from a local abattoir. Full
depth explants were excised using a 6 mm diameter biopsy
punches from the medial aspect of the medial condyle of
individual joints as previously described.22
2.7 DEX uptake into cartilage using PBAE–DEX
A polytetrafluoroethylene (PTFE) transport chamber was designed
and manufactured to study one-way diffusion of solutes entering
into cartilage;22 the chamber walls were treated with casein to
block non-specific binding of solutes to PTFE surfaces. Cartilage
disks (6 mm diameter,B0.4 mm thick) were cut in half, weighted
and placed in one of the holding slots machined into the chamber.
The chamber facing the superficial zone was filled with 50 mL of a
known concentration of PBAEs-drug formulation in PBS supple-
mented with protease inhibitors; the other chamber side was filled
with 50 mL of PBS containing protease inhibitors alone. The
chamber was then placed in a Petri dish containing dH2O and
covered to minimize evaporation then placed inside an incubator
at 37 1C; stagnant layers at cartilage surfaces were prevented by
placing the dish on a slow-speed rocker. At required intervals a
sample was removed, washed in copious amount of water and
placed in an Eppendorf containing 1 mL of digestion buffer.
Experiments were performed on triplicate samples originated
from 3 different animals.22
Comparison of the drug uptake, after a certain exposure
time (t), was performed between a solution of dexamethasone
phosphate (DEX-P) at the advised concentration of 4.4 mgmL1,
equivalent to 4 mg mL1 of DEX, and a solution of PBAE–DEX
containing the same amount of steroidal drug as described in
the equation below.
DEX uptake ratio tð Þ ¼
DEX
mg cartilage
using PBAEDEXðtÞ
DEX
mg cartilage
using DEX PðtÞ
(1)
2.8 Cartilage digestion
Cartilage samples were digested using a phosphate buffer 0.2 M
at pH = 6.8 containing 300 mg L1 of papain, EDTA 1 mM and
dithiothreitol (DTT) 2 mM. Samples were placed in 1 mL of the
digestion buffer and incubated at 50 1C for 24 hours.
2.9 DEX quantification
Dexamethasone in the digestion buffer was quantified through
reverse phase-HPLC. An Agilent series 1100 HPLC system was
equipped with a TeknoKroma TRACE EXCEL 120 ODSB 5 mm
analytical column maintained at 25 1C. The injection volume
was 25 mL, the mobile phase was PBS : acetonitrile : glacial acetic
Fig. 2 Chemical structure and coding system of compounds used.
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acid 70 : 26 : 4 (isocratic) with a flow rate of 1 mL min1 and the
detector was a UV spectrophotometer at 244 nm.22
2.10 Determination of PBAE diffusion coefficient in cartilage
Amino terminated PBAEs were fluorescein-tagged (PBAE-FITC)
using FluoroTagt FITC Conjugation Kit (Sigma, UK) according
to manufacturer’s recommendations.
The diffusion coefficients of each PBAE were determined
using the same PTFE transport chamber and arrangements
described in ref. 22. The ratio of fluorescence between the two
sides of the cartilage was plotted against diffusion time (t) and
fitted with the following equation using R (ver. 3.6),30 in order
to identify the ‘‘break-through time’’ (tlag);
Ratio fluorescence
between cartilage sides
ðtÞ ¼
t tlag
   K t4 tlag
0 to tlag
(
(2)
where K is related to PBAE steady state flux. Then, the diffusion
coefficient (D) was calculated as:31
D ¼ d
2
6tlag
(3)
where:
d is the cartilage sample thickness.
Experiments were performed on triplicate samples origi-
nated from 3 different animals (for a total of 9 measurements).
2.11 Data analysis
Hieratical clustering was carried out using R and the ‘‘stats’’
package.30 Manhattan distance between PBAEs and complete
distance between clusters were used. Partial Least Square (PLS)
regression analysis between PBAEs characteristics and DEX
uptake after 1 and 10 min of contact was carried out using R
(ver 3.6)30 and the ‘‘plsdepot’’ package.32
Clustering and PLS were performed utilizing physical and
chemical parameters of amine and acrylate components of each
PBAE obtained from PubChem library (logP, TPSA, Complexity,
Heavy Atom Count, Volume 3D, X_Steric Quadrupole 3D, Y_Steric
Quadrupole 3D, Z_Steric Quadrupole 3D); along with parameters
related to the repeated polymeric unit (amine + acrylate) calculated
through ChemDraw. These included molecular weight (MW),
boiling point (BP); melting point (MP); critical volume (CV), Gibb’s
free energy (GFE), logP (partition-coefficient between two immisci-
ble phases at equilibrium which is proportional to hydrophobicity),
solubility (logS), pKa, molar refractivity (CMR), heat of formation
(HtF) and the topological polar surface area (TPSA), which represent
the total area of all polar atoms (mainly oxygen and nitrogen)
including their affixed hydrogen atoms. Besides these computation-
ally derived characteristics, experimentally determined properties of
the PBAEs such as Mw, Mn, zeta potential, size, drug loading and
diffusion coefficient through cartilage (D) were also employed.
The choice of number of PLS components to describe the
role of different PBAEs chemical-physical properties on the
uptake of DEX into cartilage was carried out determining the
minimum number of PLS components that return at least 80%
of the initial input data VAR and an inflection in the scree
plot representing the root mean squared error (RMSE) of the
predictions at different number of PLS components.33,34
2.12 Ex vivo model of post-traumatic osteoarthritis
Cartilage disks were obtained as described before and equili-
brated in serum free medium (low-glucose DMEM (Gibco, UK)),
supplemented with 10 mM HEPES buffer (Invitrogen, CA),
1% ITS (corresponding to insulin 10 mg mL1, transferrin
5.5 mg mL1 and selenium 5 ng mL1), 0.1 mM nonessential
amino acids, 20 mg mL1 ascorbic acid, 100 units per mL
penicillin G, 100 mg mL1 streptomycin and 0.25 mg mL1
amphotericin B for 2 days at 37 1C in 5% CO2. Cartilage explants
were treated with IL-1a (1 ng mL1) to induce GAG loss for
8 days. The following treatments were compared: pure medium,
medium containing IL-1a, medium containing IL-1a and 100 nM
DEX delivered as either dexamethasone phosphate or through
PBAE–DEX for two different conditions: (1) a single dose of DEX
and (2) a continuous dose of DEX. Samples (n = 6) were incubated
at 37 1C in a humidified atmosphere containing 5% CO2;
medium was changed every 2 days. IL-1a was replenished at each
medium change for the sample; DEX in the ‘‘continuous dose’’
experiment was replenished at the same time as themediumwhile
for the ‘‘single dose’’ experiment, DEX was in the culture medium
for the first 2 days only. The cumulative GAG variation of the
cartilage from t = 0 to a certain time point (t) was determined as:
cumulative GAG variation% ðt to t0Þ
¼ GAGðtÞ GAGðt0Þ½ 
GAGðt0Þ  100
(4)
2.13 Determination of chondrocytes viability in ex vivo model
After a chosen incubation period, cartilage explants were
washed in PBS and a slice about 0.5 mm thick was cut from
the disk centre using stainless steel single-use sterile surgical
scalpels (Fisher, UK) as described in Fig. S1 (ESI†).22
Slices were stained in the dark with fluorescein diacetate
(FDA; 4 mg mL1 in PBS) and propidium iodide (PI; 40 mg mL1
in PBS) for 3 min then they were rinsed in fresh PBS. Images of the
cartilage located in close proximity from the cartilage outer surface
in contact with the medium were taken with an epifluorescent
microscope (Leica DM, IRB) using a 10 objective. Viability of
chondrocyte in the explants cartilage was assessed as FDA stained
viable cells in green and PI stained non-viable cells in red.11
Mitochondrial activity of chondrocytes in the cartilage plugs
after incubation in media containing IL-1a (1 ng mL1) and/or
DEX for 2 and 8 days was assessed through the MTT assay.35
2.14 Cartilage GAG content determination
The amount of GAG present in the cartilage samples before and
after incubation in medium was determined through the
DMMB (Dimethyl-Methylene Blue) assay.36
2.15 Statistical analysis
Drug uptake comparison between PBAEs and DEX-P at each
time point was performed through one tail t-test with a level of
significance of 0.05. GAG content was analyzed using one-way
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ANOVA to determine any significant difference between themean
values, this was followed by Tukey’s post hoc test (p o 0.05). All
statistical analyses were carried out using R.30
3 Results
3.1 DEX uptake
DEX uptake in cartilage increased with exposure time; compared
to DEX-P the efficacy of PBAE with conjugated DEX depended on
all the three constituents of the drug delivery system (amine,
acrylate and end-capping). For a given PBAE backbone (amine
and acrylate), end-capping with e2 resulted in a superior per-
formance than e1 (Fig. 3). Not all PBAEs tested had a statistically
significant effect on enhancing DEX uptake compared to
DEX-P; furthermore, the effect of PBAEs on DEX uptake was
not univocal as some significantly decreased uptake (Fig. 3).
Numerous PBAEs prepared using the longest acrylate molecule
(acrylate C) had very poor DEX uptake at the shortest contact
Fig. 3 Uptake profile of DEX in cartilage using different PBEAs (columns in panel represent individual acrylates and row amines with letters and numbers
correspondence as described in Fig. 2) end-capped with e1 (blue) and e2 (red) conjugated to DEX compared to pure DEX-P. (mean and 95% CI, * and #
represent points with p o 0.05 compared to DEX-P for e1 and e2 respectively).
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time tested (1 min) while resulted in a statistically significant
drug uptake improvement after 5 and 10 min (Fig. 3 and 4).
Clustering of the PBAEs library (Fig. 4) was predominantly
influenced by the acrylate constituent of the polymer; the
efficacy of the PBAEs tested was in good agreement with the
obtained clustering with poorly performing polymers close to
one another and, similarly, highly performing PBAEs at short
distances in the dendrogram.
The most effective polymer among those tested was A5–e2; it
returned a DEX uptake almost 8 folds higher than DEX-P after
10 min of contact between cartilage samples and fluid contain-
ing the PBAE–DEX conjugate.
3.2 Feature selection in PBAE efficacy
The RMSE of the predictions against the experimental data of
DEX uptake after 1 min using PBAEs decreased with increasing
number of PLS components (Fig. 5a); simultaneously, R2 of
predictions increased (Table 1 and Fig. S3a, ESI†). The transi-
tion from 4 to 5 components resulted in an inflection in the
scree plots (Fig. 5a and Fig. S3a, ESI†), particularly for the R2 of
Fig. 4 Ratio of DEX uptake in cartilage using different PBEAs end-capped with e1 (a) and e2 (b) conjugated to DEX compared to pure DEX-P and
correspondence to clustering based on physical chemical properties of PBAE.
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the PBAE variables; thus 5 PLS components were selected to
describe the variation within this dataset of PBAE–DEX conjugates
uptake of drug in cartilage. PLS prediction of DEX uptake for each
of the PBAE–DEX in the library closely match the experimental
data (Fig. S4a, ESI†) with residual not showing clear patterns
(Fig. S4b, ESI†) and normally distributed (Fig. S4c and d, ESI†).
Similarly, the RMSE of the predictions against the experi-
mental data of DEX uptake after 10min using PBAEs decreased with
increasing number of PLS components (Fig. 6a); simultaneously, R2
of predictions increased (Table 2 and Fig. S3b, ESI†). The transition
from 5 to 6 components resulted in an inflection in the scree plots
(Fig. 6a and Fig. S3b, ESI†), particularly for the R2 of the PBAE
variables; thus 6 PLS components were selected to described the
variation within this dataset. Also in case of 10 minute uptake, PLS
prediction of DEX uptake for each of the PBAE–DEX in the library
closelymatch the experimental data (Fig. S5a, ESI†) with residual not
showing clear patterns (Fig. S5b, ESI†) and normally distributed
(Fig. S5c and d, ESI†).
The loading plot for the two first PLS components of the
different input parameters (the characteristics of PBAEs i.e.
Fig. 5 PLS analysis for DEX uptake ratio at t = 1 min. Scree plot of PLS
analysis with respect to number of components in the PLS regression and
the RMSE of the prediction; curve inflection (elbow) indicated with an
arrow (a). Loading plot of the first two PLS components describing the
relationships between input parameters for the set of PBAEs tested (green)
and the predicted DEX uptake ratio for the two end-capping agents (dark
blue) (b).
Table 1 R2 on dependent (uptake of DEX in cartilage after 1 min) and
independent variables associated to each PLS components
Number of components X–R2 X–R2 cum Y–R2 Y–R2 cum
1 0.27 0.27 0.16 0.16
2 0.18 0.45 0.10 0.26
3 0.06 0.51 0.08 0.35
4 0.15 0.67 0.03 0.37
5 0.10 0.77 0.02 0.40
6 0.05 0.82 0.03 0.43
7 0.02 0.84 0.07 0.50
8 0.03 0.87 0.02 0.53
9 0.03 0.90 0.02 0.55
10 0.04 0.93 0.01 0.56
Fig. 6 PLS analysis for DEX uptake ratio at t =10 min. Scree plot of PLS
analysis with respect to number of components in the PLS regression and
the RMSE of the prediction; curve inflection (elbow) indicated with an
arrow (a). Loading plot of the first two PLS components describing the
relationships between input parameters for the set of PBAEs tested (green)
and the predicted DEX uptake ratio for the two end-capping agents (dark
blue) (b).
Table 2 R2 on dependent (uptake of DEX in cartilage after 10 min) and
independent variables associated to each PLS components
Number of components X–R2 X–R2 cum Y–R2 Y–R2 cum
1 0.21 0.21 0.13 0.13
2 0.09 0.30 0.12 0.25
3 0.20 0.50 0.08 0.33
4 0.17 0.67 0.07 0.40
5 0.05 0.73 0.05 0.45
6 0.10 0.83 0.02 0.47
7 0.03 0.86 0.03 0.50
8 0.02 0.88 0.04 0.54
9 0.02 0.91 0.03 0.57
10 0.02 0.93 0.02 0.59
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zeta potential, amine component Mw) and the predicted DEX
uptake for both end-capping agents tested (Fig. 5b and 6b)
provides a visual representation of the relationships between
dependent and independent variables. Input parameters within
the loading plot adjacent to the modelled outcome are closely
related, in case of opposite directions the relation between
input variable and output is opposite; analogously, input para-
meters perpendicular to an outcome correspond to variables
with little influence on that outcome. TSPA of PBAE, amine and
acrylate correlated to DEX drug uptake after 1 min (Fig. 5b) and
the pKa of the polymer, diffusion coefficient and zeta potential
of each PBAE were positively correlated to the drug uptake after
10 min (Fig. 6b), while solubility (log S) had little impact. The
importance of each different PBAE characteristics (input para-
meters) considered in the PLS regression of DEX uptake
revealed that, for both end-capping agents, the most positively
correlated factors for PBAEs end-capped with e1 were the diffusion
coefficient, zeta potential and pKa, while for e2, solubility was
important after 1 min and log P at 10 min. Parameters related
to PBAEs chain length (Mw and Mn) and volume had negative
correlations; on the contrary the hydrodynamic size of the
conjugates minimally influenced drug uptake (Fig. 7 and 8).
3.3 Ex vivo model of post-traumatic osteoarthritis
Cartilage samples cultured ex vivo in medium showed a progressive
increase of the GAG content over a period of 8 days up to 70% from
the initial value (Fig. 9a); when IL-1a was added to the medium a
progressive ECM degradation was observed and more than 50% of
the initial GAGwas lost after 8 days. The simple addition of A5–e2 to
the medium containing IL-1a reduced the osteolytic activity of IL-1a
and after 8 days the cartilage samples had the same amount of GAG
as at t = 0 (p4 0.05). When DEX was delivered continuously no
degradation of GAG was observed and the tissues had the same
amount of GAG as the controls (p 4 0.05), furthermore no
difference was observed between DEX-P or the same amount of
steroidal drug conjugated to A5–e2.
Epifluorescent images of the cartilage ex vivo sample (Fig. 9b)
showed that control samples did not exhibit dead cells (would
appear red) but only viable chondrocytes (in green); the addition
of IL-1a results in dead cells being observed close to the inter-
face between cartilage and fluid after 2 days of incubation; when
incubation was prolonged to 8 days dead cells also were visible
further away from the superficial area. Addition of DEX reduced
the number of not viable chondrocytes, particularly after 8 days
of incubation regardless of steroidal drug being supplemented
as DEX-P or conjugated to A5–e2. Not viable chondrocytes were
visible in cartilage exposed to IL-1a and A5–e2 in increasing
amount from 2 to 8 days of incubation. Mitochondrial activity
on the chondrocytes in the cartilage samples was not affected by
the presence of IL-1a and/or DEX when exposed for 2 days
(p4 0.05); however, when the contact was prolonged to 8 days,
chondrocytes viability was lower when the media contained
IL-1a or IL-1a and A5–e2 (po 0.01). Mitochondrial activity after
incubation of cartilage for 8 days with IL-1a and DEX delivered
with A5–e2 continuously did not exhibit statistically significant
differences (p 4 0.05) (Fig. 10).
A single dose of DEX, either as DEX-P or conjugated to
A5–e2, was not capable of achieving the same suppression of IL-1a
induced GAG degradation (Fig. 11); after 8 days of exposure to
IL-1a GAG loss was B10% compared to the initial value for a
Fig. 7 PLS derived correlations for the different PBAEs characteristic (input parameters within the model) and DEX uptake ratio at t = 1 min for PBAE end-
capped with e1 (a) and e2 (b).
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single dose and a GAG increase of B50% for the continuous
dose. A statistically significant difference was observed between
DEX-P or the same amount of steroidal drug conjugated to A5–e2
delivered as ‘‘single dose’’ (p o 0.05). Moreover, when cartilage
samples were exposed to a single delivery of DEX the mitochondrial
activity after 8 days was lower than the control samples or the
tissues treated with a continuous dose of DEX (Fig. 10).
4 Discussion
Cartilage structure is a barrier to the penetration of even small
molecules making drug delivery in this tissue a yet unsolved
challenge; this is further complicated by the rapid clearance of
drugs once in cartilage.12,13 Even though drugs with potential
biological activity against OA have been identified, their localised
delivery into cartilage is a requisite for their translation into actual
patient treatments. PBAEs could provide a versatile delivery system
for the localisation of drugs in cartilage through a higher uptake
and longer retention.22 DEX uptake was 8 folds higher (Fig. 3) than
the current medical formulation of DEX-P for the most effective
PBAE in the current library (A5–e2); the use of this polymer
would allow the concentration of DEX in cartilage to be above
the therapeutic threshold for a longer period of time leading to
improved outcomes.
The amines employed in this work did not present other
moieties where the succinylated DEX could have reacted; for
example in the vast PBAEs library tested for DNA transfection
activity, some amine had also hydroxyl groups.17,18 The drug
conjugation to such PBAEs would have likely resulted in the
formation of ester bonds between the hydroxyl group and the
succinylated DEX along the PBAE chain beside the formation of
amine bonds at the two extremities. End-capping is well known
to be a key in influencing the efficacy of PBAEs when employed
in the delivery of DNA in cells;18,37–39 the pivotal role of the end-
capping molecule in such circumstances has been attributed to
effect of the end-capping molecule on the endosomial buffering
capacity of PBAEs.40 Such buffering capacity depends on the
presence of secondary and tertiary amines that are highly
protonatable at physiological pHs.41 The proton inflow due to
the buffering ability of PBAEs in cartilage could results in a
further increase in the negatively charged GAG chains thus
augmenting the electrostatic attraction between PBAE and
cartilage ECM components. It is, therefore, reasonable to expect
that such mechanism would also impact the ability of PBAE to
diffuse through cartilage. PBAEs end-capped with e2 would have a
higher buffering capacity than the corresponding counterparts end-
capped with e1 because of the presence of additional secondary
amine in the end-capping agent (Fig. 2); consequently, this theory
would be in agreement with the experimentally observed higher
drug uptake of PBAEs end-capped with e2 than e1 (Fig. 3). Thus, our
results prove that end-capping is not only a step necessary to allow
conjugation between drug and polymer chain, but also can be
employed to maximise the efficacy of the resulting pro-drug as
drug delivery system for cartilage. The impact of the end-
capping agent on the efficacy of the PBAE is also well described
by the different importance of each characteristics of the
polymer, along with the amine and acrylate components, had
on drug uptake when the same PBAE backbone presented
different extremities (Fig. 7 and 8).
Fig. 8 PLS derived correlations for the different PBAEs characteristic (input parameters within the model) and DEX uptake ratio at t = 10 min for PBAE
end-capped with e1 (a) and e2 (b).
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The choice of 10 min as the longest uptake end-point was
guided by the evidence that drugs injected intra-articularly
experience clearance from the joint space in well under 1 hour.42
During the clearance the concentration of the drug in the joint
space decreases from the moment of injection; therefore pro-
longed experiments with constant and high concentration of
drug in the liquid phase in contact with cartilage tissues would
not be a proper representation of the phenomena. However,
clearance also depends on the size of the molecule with smaller
molecules exhibiting shorter half-lives;42 thus it is possible that
PBAEs–DEX would remain in the joint space for longer than
DEX-P and, therefore, the experimental setting could under-
estimate the efficacy of the delivery system. Another potential
aspect to consider is the retention of DEX in the cartilage tissue
after uptake; A5e2–DEX allowed concentrations of DEX in the
cartilage explants for almost 5 hours (data not shown) compared
to about 2 hours of DEX-P.22 The limited efficacy in preventing
IL-1a induced GAG degradation observed when delivered as
single dose (Fig. 11) can be explained by the wash-out of the
steroidal drug compared to the continuous dosing approach.
Chemometrics (the use data analytic techniques in chemical
systems) were applied here in order to draw inference from the
DEX uptake and PBAE structure, because of the size of the
PBAEs library and the number of properties characterising each
polymer. Principle component analysis (PCA) and partial least
squares (PLS) regression are two chemometrics techniques.
They perform variables reduction through the construction
of components that are linear combinations of the original
independent variables. These two methods enable features
selection for the chosen responses, reduction of models over-
fitting and more easily interpretable models.43 Both PCA and
PLS have been applied in drug discovery and drug design44,45 as
a tool to identify promising candidate molecules or to identify
correlations.46,47 Furthermore, PCA was employed to elucidate
Fig. 9 GAG content cumulative variation in cartilage explants cultured
with basal media or medium containing 1 ng mL1 of IL-1a and a
continuous dose of DEX 100 nM with or without A5–e2; * represents
points where the difference between DEX-P and A5–e2–DEX was statis-
tically significant (p o 0.05) (a). Epifluorescent images of bovine cartilage
explants stained with FDA and PI to assess chondrocyte viability after
2 days incubation (top row) and 8 days (bottom row) with basal media or
medium containing 1 ng mL1 of IL-1a and DEX 100 nM with or without
A5–e2. Green indicates viable cells and red indicates non-viable cells. Bar
represent 80 mm (b).
Fig. 10 Mitochondrial activity in cartilage explants cultured with basal
media or medium containing 1 ng mL1 of IL-1a and either a single or a
continuous dose of DEX 100 nM with or without A5–e2. * Represents
points where the difference was statistically significant (p o 0.05).
Fig. 11 GAG content cumulative variation in cartilage explants cultured
with basal media or medium containing 1 ng mL1 of IL-1a and a single
dose of DEX 100 nM with or without A5–e2. * Represents points where the
difference between DEX-P and A5–e2–DEX was statistically significant and
# Represents points where the difference between control and A5–e2–
DEX was statistically significant (p o 0.05).
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the physico-chemical properties of PBAEs that are the key
drivers of gene transfection, uptake and viability in human
primary glioblastoma cells.48 The main difference between PCA
and PLS is that in PCA the loading of each variable is deter-
mined in order to maximise the variability of the initial data set
without considering the impact of the resulting components on
the dependent variables (process outcomes). On the other
hand, in PLS the components are constructed to maximise
their predictive power hence PCA is an unsupervised learning
technique while PLS is a supervised technique. We chose PLS
regression to elicit the role of PBAE properties with regard to
DEX uptake in cartilage and to identify the physicochemical
parameters of the polymers that most affect the delivery system
efficacy. Because PBAEs properties are highly correlated (Fig. S2,
ESI†) and multicollinearity would affect the model outcomes,
standard predictive modelling techniques based on standard
regression could have not be used. In order to provide meaningful
information, PLS predictions must accurately describe the experi-
mental data obtained; this was the case here as the values of DEX
uptake obtained from the model were in good agreement with the
experimentally gathered results. The most important PBAEs
features in cartilage uptake identified were zeta potential, pKa
and diffusion coefficient of the polymer. pKa and zeta potential
relate to the intensity of the electrostatic interaction between
PBAEs and ECM components (GAGs) as pKa describes the level
of protonation of the amine groups present in the PBAE backbone
and zeta potential is a direct quantification of the charges exhib-
ited. Furthermore, the diffusion coefficient is the most relevant
characteristic of the polymer for the overall uptake after 10 min of
e1 end-capped PBAEs. The greater the size of PBAE (Mw and Mn)
the more sterically hindered the diffusion through the cartilage
tissue, explaining the negative correlation between DEX uptake and
properties such as Mw and Mn of PBAEs, amine and acrylate MW,
complexity, number of heavy atoms and 3D estimated volume.
Drug uptake does not guarantee biological activity, for example,
once DEX interacted with the delivery system, its anti-inflammatory
activity could be reduced in light of a possible lower availability;
hence we also tested the ability of PBAEs in delivering DEX to
counteract the cartilage GAG degradation induced by IL-1a in an
experimental setting similar to that used to by Bajpayee et al.11 IL-1a
is a cytokine observed during inflammation and it is well known to
be involved in cartilage degradation,49 similarly DEX is known to
modulate IL-1a mediated cartilage degradation.50 The efficacy in
delivery DEX in such ex vivomodel was carried out using only A5–e2
as this polymer was the most effective in the synthesised PBAEs
library (Fig. 3). Delivery of DEX was carried out in two ways either
continuously or as single dose. The observed GAG content progres-
sive decline of the samples exposed to IL-1a, and ECM rescue when
cultured also in the presence of DEX, were well in agreement with
the general knowledge (Fig. 9). This results show an increase in GAG
content over 8 days for explants cultured under basal conditions
(serum-free medium + 1% ITS) while other reports using this
model11,49 showed a gradual loss of GAG with time in young bovine
explants cultured ex vivo. These discrepancies could be the results of
different animal breeds among studies, also discordant storage
conditions during transport from the abattoir to the lab and the
duration of such transport could impact viability and ability to
recover of chondrocytes in the samples.
The PBAE-based delivery system developed in this work was
as effective as the commercial formulation of DEX-P when delivered
continuously demonstrating that DEX remained active when
delivered through the proposed systems. Furthermore, when
DEX was delivered as a single dose, its efficacy in suppressing
GAG degradation was greater than DEX-P in the same conditions
(Fig. 9 and 11) thus further highlighting the improved drug
localisation achieved through the delivery system presented.
The absence on negative impact of the PBAEs-based delivery
system on the chondrocytes viability (Fig. 10) was essential in
demonstrating the feasibility of the technology beyond the initial
uptake. As DEX is bound to the PBAE by an ester bond, its release
is controlled by the hydrolysis of such bond. This reaction is
relatively common in aqueous environments, even without the
presence of enzymes, and was shown to occur over a few days.22
Conjugation of DEX to polymers chain is not restricted to ester
bonds but can also be achieved with a hydrazone linkage that
results in slower hydrolysation kinetics;11 it is, therefore, foresee-
able that further drug localisation could be achieved considering
also this element of the delivery system, potentially also combining
slow and fast releasing agents. Furthermore, IL-1a induced GAG
decline was reduced when cartilage samples were exposed to A5–e2
only (no DEX present); this outcome could be attributed to the
competitive polymer diffusion through the tissue preventing the
cytokine uptake and such its activity.
5 Conclusions
OA is still effectively untreatable and only disease management
therapies are recommended; moreover, because of the obstacles
to drug delivery posed by cartilage structure, any future drug for
such disease will undoubtedly require an effective delivery
system to guarantee localisation of the active molecule in the
tissue. PBAEs have the potential to be a solution to cartilage
drug delivery challenges as the currently known best effective
member of the polymer class already provides an 8-folds
increase in cartilage uptake of DEX, a drug clinically used in
OA management, compared to the clinical formulation. Further
optimisation could reveal even more effective polymers.
Chemometrics elicited what chemical parameters are key
drivers of PBAEs performance as drug delivery systems for
cartilage, this knowledge can provide blueprints for the in silico
development and design of the next generation drug delivery
systems for cartilage. This chemometrics based predictive
model also allows the computational estimation of the efficacy
of any unknown PBAEs from the given amine and acrylate
components using physico-chemical parameters available from
databases or using computational methods capable of predicting
the required properties from the chemical structure.
These predictive principles can be applied in computer
based drug discovery designed to pursue high-throughput screening
of a wider range of PBAEs instead of the expensive and time
consuming lab bench approach of trial and error. Such simulations
will contribute to a more cost-effective use of resources accelerating
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the bench to market process and such shortening the time before
patients could benefit from a more effective drug delivery systems
enabling better treatments of cartilage diseases.
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